10-Q: Goldenwell Biotech Reports Q2 2026 Results, Faces Going Concern Doubt

Goldenwell Biotech, Inc. filed its Q2 2026 10-Q, revealing no revenue, a significant accumulated deficit, and substantial doubt regarding its ability to continue as a going concern, though it did report a minor other income from a legal settlement.

Summary

• Goldenwell Biotech, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company generated $0 in sales revenue for both the three and six-month periods ended June 30, 2026, and 2025.
• General and administrative expenses were $34,776 for the three months ended June 30, 2026, and $66,111 for the six months ended June 30, 2026.
• Net losses were $38,876 for the three months ended June 30, 2026, and $54,482 for the six months ended June 30, 2026.
• The company has an accumulated net loss of $1,710,598 as of June 30, 2026.
• Cash balance was $11,143 as of June 30, 2026, with a working capital of $(398,195).
• The company has a related-party loan of $140,588 from its CEO, Shuang Liu.
• A prior period restatement corrected errors related to legal fees, OTCQB fees, and service revenue recognition.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a very negative score due to the company's continued lack of revenue, significant accumulated deficit, and substantial doubt about its ability to continue as a going concern, despite some minor positive adjustments from prior period restatements.

Positives

• A minor other income of $13,969 was recognized for the six months ended June 30, 2026, from a legal settlement.
• The company recognized $1,860 in Other Income for the six months ended June 30, 2026, related to abandoned sales contracts (breakage).
• The prior period restatement corrected some accounting errors, leading to adjustments in reported figures for prior periods.
• The company believes it has sufficient cash to fund operational expenses through December 31, 2026.

Negatives

• The company generated $0 in sales revenue for the six-month periods ended June 30, 2026, and 2025.
• The company has sustained an accumulated net loss of $1,710,598 since its inception.
• The company's working capital balance was $(398,195) as of June 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has an outstanding related-party loan of $140,588 from its CEO.
• Inventories totaling $174,745 were impaired and written down as of December 31, 2025, due to expiration.
• Disclosure controls and procedures were found to be not effective.

Risks

• The company's continuation as a going concern is dependent on its ability to generate revenues and obtain capital from third parties.
• Failure to obtain necessary financing could lead to the failure of the business.
• Existing shareholders will experience dilution if the company successfully completes an equity financing.
• The company has no financing arranged and cannot guarantee it will be able to raise sufficient funding.
• The company estimates needing approximately $5,000,000 to construct manufacturing facilities and set up equipment, which would take approximately one year.
• The company's disclosure controls and procedures were not effective, raising concerns about the reliability of financial reporting.

Future Outlook

The company plans to increase sales of its products over the next 12 months. It estimates needing approximately $5,000,000 to construct manufacturing facilities and set up equipment, which is expected to take about one year. Additional funding is anticipated through equity financing, though there is no guarantee of success. The company believes it has sufficient cash to fund ongoing operational expenses through December 31, 2026.

Management Comments

• The company's continuation as a going concern is dependent upon, among other things, its ability to generate revenues and its ability to obtain capital from third parties.
• There is no assurance that the Company will be successful in these efforts.
• The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
• The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities.
• Actual results could differ from those estimates.
• We have not generated positive cash flows from operating activities.
• In the absence of such financing, our business will fail.
• There are no assurances that we will be able to achieve further sales of our common stock or any other form of additional financing.

Industry Context

StockSavvy.ai notes that Goldenwell Biotech operates in the health care and supplements sector, a highly competitive industry. The company's current financial state, characterized by zero revenue and significant losses, places it at a severe disadvantage compared to established players and even other early-stage biotech firms that typically have some form of product development pipeline or early-stage revenue streams.

Comparison to Industry Standards

• Most early-stage biotech companies aim to generate revenue through product sales, licensing agreements, or partnerships, even before full commercialization. Goldenwell Biotech's complete lack of revenue is a significant deviation from industry norms.
• Companies in the health care and supplements sector typically require substantial R&D investment and often have a clear path to market. Goldenwell Biotech's stated need for $5 million for manufacturing facilities suggests a very nascent stage of development, far behind industry standards for companies of its purported age.
• The significant accumulated deficit of over $1.7 million is common for early-stage companies, but it is usually accompanied by tangible progress in product development or market entry, which appears to be lacking here.

Corporate Governance

Legal Proceedings

• The Company is not currently subject to any legal proceedings.
• There are no pending legal proceedings that, in the opinion of management, are likely to have a material adverse effect on the Company's business, financial condition, or results of operations.

Related Party Transactions

• The Company borrowed $140,588 from Shuang Liu, the Chief Executive Officer, as of June 30, 2026.
• The Company entered into a one-year technical development and business cooperation arrangement with Trefoil (Hong Kong) Life Science Research Center, where CEO Shuang Liu also serves as CEO of Trefoil.
• Unearned service revenue of $100,000 as of June 30, 2026, is related to the agreement with Trefoil.

Stakeholder Impact

• Shareholders: Potential for significant dilution if equity financing is successful; continued risk of business failure if financing is not obtained.
• Creditors: The company's going concern issues and lack of revenue pose a risk to creditors.
• Employees: Uncertainty regarding the company's future operations and ability to fund payroll and operations.
• Suppliers: Potential for non-payment if the company fails to secure financing or generate revenue.

Next Steps

• Increase the sales of its products.
• Construct manufacturing facilities, including locating a site, installing a workshop, and setting up equipment.
• Train workforce.
• Obtain necessary capital through debt or equity financing.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, a substantial accumulated deficit, and significant doubt about its ability to continue as a going concern. The need for substantial capital, coupled with the lack of financing arrangements and potential for significant shareholder dilution, presents an extremely high-risk investment profile. The ineffective disclosure controls further add to the concerns.

Keywords

Biotech, Healthcare, Supplements, Form 10-Q, Financial Statements, Going Concern, Related Party Transaction, Inventory Impairment